Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

AACR 2009: DNA profiling for bladder cancer

AACR 2009

18 - 22 Apr 2009

Published: 30 Apr 2009

Views: 16730

Rating:

Save

Dr Gangning Liang - Associate Professor of Research, Department of Urology, University of Southern California

Gangning Liang, M.D., Ph.D., associate professor of research, department of urology, University of Southern California, presents at AACR 2009, Denver: DNA methylation profiling reveals a field defect in bladders with cancer and a distinct hypomethylated pattern in non-invasive bladder tumours

Related Videos

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer

Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer ( Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy )

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

More from ecancer